Effect of saroglitazar in South Indian patients with diabetic dyslipidemia uncontrolled on a moderate-intensity statin and the association of PPAR α and γ gene polymorphisms with its response

Background: Diabetic dyslipidemia is associated with atherosclerosis risk factors and cardiovascular disease. Saroglitazar a dual PPAR α γ agonist approved initially for diabetic later managing non-alcoholic steatohepatitis hyperglycemia in T2DM. This study was conducted to estimate the association of studied gene polymorphisms among patients at baseline triglyceride response saroglitazar administration. Methods: A total 54 who are not controlled i.e., triglycerides (TG)>200 mg/dl moderate intensity atorvastatin (≥10 mg) were recruited study. All given 4 mg once daily 12 weeks. PPARα single nucleotide (SNPs) rs1800206, rs4253778, rs135542 those PPARγ rs3856806, rs10865710, rs1805192 genotyped by real-time PCR. Results: (67% female) mean age 48.01±6.73 years There significant decrease TG (36.9%) from 292.33±83.81mg/dl (mean±SD) 184.46±95.90 (<0.001) HbA1c (0.66%) 8.5% 7.8% (<0.001). variants did show any lowering response. Conclusions: 4mg effectively decreases TG, non-HDL-C levels, no major adverse events, polymorphisms.